• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cellular and molecular aspects of pancreatic cancer.胰腺癌的细胞和分子层面
Acta Histochem. 2016 Apr;118(3):305-16. doi: 10.1016/j.acthis.2016.01.009. Epub 2016 Feb 8.
2
The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.活化星状细胞介导的旁分泌信号、代谢和癌免疫学在胰腺导管腺癌中的关键作用。
Mol Cancer. 2018 Feb 19;17(1):62. doi: 10.1186/s12943-018-0815-z.
3
Aquaporins in pancreatic ductal adenocarcinoma.水通道蛋白在胰腺导管腺癌中的作用。
APMIS. 2021 Dec;129(12):700-705. doi: 10.1111/apm.13184. Epub 2021 Oct 18.
4
Modeling pancreatic cancer in mice for experimental therapeutics.在小鼠中模拟胰腺癌用于实验治疗。
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188554. doi: 10.1016/j.bbcan.2021.188554. Epub 2021 May 1.
5
New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌的新诊断与治疗方面
Curr Med Chem. 2017;24(28):3012-3024. doi: 10.2174/0929867324666170510150124.
6
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.胰腺癌的靶向治疗及未来障碍
Anticancer Res. 2018 Dec;38(12):6591-6606. doi: 10.21873/anticanres.13026.
7
Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins.基质在胰腺导管腺癌中的作用：聚焦细胞外基质蛋白的综述
Front Immunol. 2021 Apr 6;12:612271. doi: 10.3389/fimmu.2021.612271. eCollection 2021.
8
The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.胰腺导管腺癌中宿主组织与免疫细胞的相互调控：新的见解和治疗意义。
Mol Cancer. 2019 Dec 13;18(1):184. doi: 10.1186/s12943-019-1117-9.
9
Perspectives in the treatment of pancreatic adenocarcinoma.胰腺腺癌的治疗前景
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
10
Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer.白血病抑制因子：胰腺癌的潜在生物标志物和治疗靶点。
Arch Immunol Ther Exp (Warsz). 2021 Feb 25;69(1):2. doi: 10.1007/s00005-021-00605-w.

引用本文的文献

1
Current Screening Strategies for Pancreatic Cancer.胰腺癌的当前筛查策略
Biomedicines. 2022 Aug 23;10(9):2056. doi: 10.3390/biomedicines10092056.
2
ID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human.ID1 标记了小鼠和人类胰腺导管腺癌的肿瘤发生。
Sci Rep. 2022 Aug 8;12(1):13555. doi: 10.1038/s41598-022-17827-3.
3
Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model.人羊膜间充质干细胞在原位异种移植小鼠模型中减弱胰腺癌细胞增殖和肿瘤生长。
Stem Cell Res Ther. 2022 Jun 3;13(1):235. doi: 10.1186/s13287-022-02910-3.
4
Role of Nrf2 in Pancreatic Cancer.Nrf2在胰腺癌中的作用。
Antioxidants (Basel). 2021 Dec 30;11(1):98. doi: 10.3390/antiox11010098.
5
Attenuation of Pancreatic Cancer In Vitro and In Vivo via Modulation of Nrf2 and NF-κB Signaling Pathways by Natural Compounds.天然化合物通过调节 Nrf2 和 NF-κB 信号通路抑制胰腺癌细胞体外和体内生长。
Cells. 2021 Dec 16;10(12):3556. doi: 10.3390/cells10123556.
6
Engineering of biomaterials for tumor modeling.用于肿瘤建模的生物材料工程
Mater Today Adv. 2020 Dec;8. doi: 10.1016/j.mtadv.2020.100117. Epub 2020 Nov 12.
7
Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines.熊果酸聚乳酸-羟基乙酸共聚物纳米粒对胰腺导管腺癌细胞系的体外细胞毒活性评价
Materials (Basel). 2021 Aug 29;14(17):4917. doi: 10.3390/ma14174917.
8
Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.胰腺癌的诊断、预测和预后分子生物标志物：临床医生概述
Cancers (Basel). 2021 Mar 3;13(5):1071. doi: 10.3390/cancers13051071.
9
CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells.CCAAT/增强子结合蛋白δ（C/EBPδ）：一种先前未被认识的肿瘤抑制因子，可限制胰腺导管腺癌细胞的致癌潜能。
Cancers (Basel). 2020 Sep 7;12(9):2546. doi: 10.3390/cancers12092546.
10
Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature.胰腺导管腺癌的放射免疫疗法：文献现状综述
Cancers (Basel). 2020 Feb 19;12(2):481. doi: 10.3390/cancers12020481.

本文引用的文献

1
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.维生素C通过靶向甘油醛-3-磷酸脱氢酶选择性杀死KRAS和BRAF突变的结肠癌细胞。
Science. 2015 Dec 11;350(6266):1391-6. doi: 10.1126/science.aaa5004. Epub 2015 Nov 5.
2
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.磷脂酰肌醇蛋白聚糖-1可识别癌症外泌体并检测早期胰腺癌。
Nature. 2015 Jul 9;523(7559):177-82. doi: 10.1038/nature14581. Epub 2015 Jun 24.
3
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.胰腺癌的全外显子组测序确定了基因多样性和治疗靶点。
Nat Commun. 2015 Apr 9;6:6744. doi: 10.1038/ncomms7744.
4
Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer.胰腺癌的分子发病机制与靶向治疗
Ann Surg Oncol. 2016 Feb;23 Suppl 2:S197-205. doi: 10.1245/s10434-015-4463-x. Epub 2015 Mar 7.
5
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.胰腺癌原发性肿瘤和转移灶中的促结缔组织增生反应
Clin Cancer Res. 2015 Aug 1;21(15):3561-8. doi: 10.1158/1078-0432.CCR-14-1051. Epub 2015 Feb 18.
6
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.通过生物相容性的脂质-聚合物杂化纳米粒共递送 HIF1α siRNA 和吉西他滨，有效治疗胰腺癌。
Biomaterials. 2015 Apr;46:13-25. doi: 10.1016/j.biomaterials.2014.12.028. Epub 2015 Jan 15.
7
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
8
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.PX-478对HIF-1α的抑制作用通过诱导胰腺导管腺癌的免疫原性细胞死亡增强吉西他滨的抗肿瘤作用。
Oncotarget. 2015 Feb 10;6(4):2250-62. doi: 10.18632/oncotarget.2948.
9
A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.一种hypusine-eIF5A-PEAK1开关调节胰腺癌的发病机制。
Cancer Res. 2014 Nov 15;74(22):6671-81. doi: 10.1158/0008-5472.CAN-14-1031. Epub 2014 Sep 26.
10
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.用于区分胰腺癌与良性胰腺疾病的血清细胞因子生物标志物组合
Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

胰腺癌的细胞和分子层面

Cellular and molecular aspects of pancreatic cancer.

作者信息

Gharibi A, Adamian Y, Kelber J A

机构信息

Developmental Oncogene Laboratory, Department of Biology, California State University Northridge, Northridge, CA 91330, USA.

Developmental Oncogene Laboratory, Department of Biology, California State University Northridge, Northridge, CA 91330, USA.

出版信息

Acta Histochem. 2016 Apr;118(3):305-16. doi: 10.1016/j.acthis.2016.01.009. Epub 2016 Feb 8.

DOI:10.1016/j.acthis.2016.01.009
PMID:26868366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5654315/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that affects nearly 50,000 patients each year. The overall 5-year survival rate for this malignancy remains the lowest of any cancer at around 7% due to limited diagnostic methods, disease aggressiveness and a lack of targeted therapeutic interventions. This review highlights the successes achieved over the past several decades as well as the significant cellular and molecular hurdles that remain in combatting this deadly disease at a translational level.

摘要

胰腺导管腺癌（PDAC）是一种致命的恶性肿瘤，每年影响近50000名患者。由于诊断方法有限、疾病侵袭性强以及缺乏靶向治疗干预措施，这种恶性肿瘤的总体5年生存率仍然是所有癌症中最低的，约为7%。本综述强调了过去几十年所取得的成功，以及在转化层面抗击这种致命疾病方面仍然存在的重大细胞和分子障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ed/5654315/cd4500f76942/nihms912437f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ed/5654315/cd4500f76942/nihms912437f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ed/5654315/cd4500f76942/nihms912437f1.jpg